Vladonix®
Studies have shown that 92% of people living in an ecologically unfavorable territory have disorders in
the immune status, manifested in a decrease in the number of CD3+, CD4+ cells, with a slight increase
in lymphocytes with the CD8+ phenotype, which indicates a reduction in the level of immunoreactiv-
ity (CD4+/CD8+). The results of RTML with ConA characterize a decrease in the functional activity of
T-lymphocytes (mainly CD8+, i.e., T-suppressors/killers). The content of CD20+ - cells, representing
a subpopulation of B-lymphocytes, did not significantly differ from normal values. Still, an increase in
the amount of immunoglobulins M and G in the blood serum was observed (Table 2).
It should be noted that the quantitative indicators of the content of CD3+ and CD4+ - cells are char-
acteristic of the lower limits of physiological fluctuations in their number in patients of this age, which
may indicate the weakening and premature aging of the immune system. As a rule, patients with a
secondary immunodeficiency state had a pronounced asthenic syndrome and significant changes in
the cardiovascular system.
Influence of VLADONIX® on indicators of cellular and humoral immunity in Table 2
individuals exposed to low doses of ionizing radiation
Indicators Before treatment After treatment with After treatment with
Leukocytes, х109/l 5,0±0,2 5,4±0,1 5,6±0,1
Lymphocytes, % 26,2±2,6 31,4±2,4 35,1±2,1
х109/l 1,51±0,08 1,64±0,05 1,87±0,05
CD3+, % 46,5±2,3 51,9±2,2 55,7±2,6*
х109/l 1,53±0,09 1,65±0,07 1,86±0,05*
CD4+, % 28,5±2,8 30,8±2,1 34,6±2,0*
х109/l 0,41±0,01 0,49±0,07 0,67±0,09*
CD8+, % 26,4±1,5 25,7±1,6 24,9±1,8
х109/l 0,43±0,05 0,42±0,03 0,46±0,07
CD4+/CD8+
1,1 1,2 1,4*
CD20+, %
х109/l 12,3±0,6 12,0±0,4 12,0±0,7
0,18±0,01 0,21±0,01 0,20±0,01
RTML, % 88,1±5,4 76,2±4,8* 70,4±4,9*
IgM, (g/l) 1,82±0,06 1,72±0,05 1,66±0,06
IgG, (g/l) 15,7±1,3 15,6±1,6 15,3±1,7
IgА, (g/l) 2,2±0,1 2,0±0,1 2,1±0,3
* P <0.05 –reliable in comparison with the indicator before treatment.
The results of the studies conducted convincingly indicate that VLADONIX® is an effective remedy for
correcting secondary immunodeficiencies that develop in response to exposure to extreme factors.
The use of VLADONIX® in combination with symptomatic agents made it possible to normalize the impaired
parameters of the immune system in 78% of cases.
As follows from the data presented above, the most significant effect from the use of VLADONIX® was
observed in relation to subpopulations of T-lymphocytes and their functional activity (a significant increase in
the content of CD3+ and CD4+ lymphocytes, normalization of the CD4+/CD8+ ratio). A less distinct reaction
took place on the part of the B-system of the immune system, probably due to its greater conservatism.
After the course of treatment with VLADONIX®, patients who received small doses of ionizing radiation
noted a significant improvement in their general condition and a decrease in the severity of the asthenic
syndrome, which always accompanies secondary immunodeficiencies.
In oncological patients, after radiation and chemotherapy, an accelerated normalization of immunological
parameters was noted compared to the control group, which led to an improvement in overall well-being
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.